search
Back to results

Novel Medications for Opiate Detoxification - 4

Primary Purpose

Opioid-Related Disorders, Substance-Related Disorders

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Clonidine
Sponsored by
Yale University
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid-Related Disorders focused on measuring Opioid-Related Disorders

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Please contact site for information.

Sites / Locations

  • VA Connecticut Healthcare System

Outcomes

Primary Outcome Measures

Withdrawal severity

Secondary Outcome Measures

Full Information

First Posted
September 20, 1999
Last Updated
June 17, 2020
Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System
search

1. Study Identification

Unique Protocol Identification Number
NCT00000279
Brief Title
Novel Medications for Opiate Detoxification - 4
Official Title
Novel Medications for Opiate Detoxification
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
September 1994 (undefined)
Primary Completion Date
August 1999 (Actual)
Study Completion Date
August 1999 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), VA Connecticut Healthcare System

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to evaluate novel medications for opiate detoxification.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders, Substance-Related Disorders
Keywords
Opioid-Related Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Enrollment
0 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Clonidine
Primary Outcome Measure Information:
Title
Withdrawal severity

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas R Kosten, M.D.
Organizational Affiliation
VA Connecticut Healthcare System
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Connecticut Healthcare System
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States

12. IPD Sharing Statement

Citations:
Citation
AM J Drug & Alc. Abuse 21(4): 453-467, 1995; Neuropsychopharm 13(4): 323-333, 1995; Neuropsychopharm 14(3): 187-193, 1996; J Pharma & Experimental Therapeutics 276(3): 1128-1135, 1996.
Results Reference
background

Learn more about this trial

Novel Medications for Opiate Detoxification - 4

We'll reach out to this number within 24 hrs